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least did not proliferate at the time examined. In addition, even
newly formed cardiomyocytes in early biopsy samples expressed
connexin 43, providing evidence for a functional coupling to
adjacent myocytes in the transplanted myocardial tissue. The
origin of the newly formed cells might be the bone marrow (3–5).
However, because in orthotopic cardiac transplantation the
atrial stumps of the donors remain in the thorax, host-derived
resident cardiac progenitor cells might also contribute to cardiac
regeneration.
Recapitulating, our results illustrate a small but persistent
increase in cardiac regeneration. This raises hope that this process
could be accelerated and therefore used therapeutically, e.g., by
growth factor application or autologous stem cell transplantation.
However, the number of regenerated cells is still low, and studies
on transplanted myocardium after repetitive rejections or myocar-
dial infarctions will show the biological relevance of cardiac
chimerism.
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Letters to the Editor
Measuring Effects of
Antiatherosclerotic Therapies
Corti et al. (1) found no difference in vessel wall area measured by
magnetic resonance imaging (MRI) between simvastatin 80 mg
and 20 mg daily over 18 months of follow-up. This might have
been due to the small sample size of 51 subjects, but it also was
probably partly due to the method of measurement.
It is important to understand that methods for measuring athero-
sclerosis give biologically distinct phenotypes (2). Traditional risk
factors account for 53% of variance (R2) of carotid plaque area, but
only 13% of carotid stenosis measured by Doppler velocities, and
only 15% to 17% of intima-media thickness (IMT). Including
IMT in a measurement of “atherosclerosis” introduces the noise of
the medial hypertrophy that is due to blood pressure. For maxi-
mum carotid IMT, sample sizes are from 468 per group for a 30%
effect size, to 30 per group for a 100% effect size over 3 years (3).
Sensitivity of measurements to effects of therapy also depends
on the location and method of the measurement. Carotid plaques
grow along the artery 2.4 times faster than they thicken (4). Most
carotid plaques are focal, with a proximal and distal end, which can
progress or regress, and this change can be captured by measuring
plaque area (5). Plaque volume is even more sensitive to effects of
treatment. We recently found that a sample of 20 patients per group
was sufficient to detect regression of plaque with high-dose atorva-
statin versus placebo in three months (6). Because coronary plaques
are diffuse, without a proximal and distal end, change in coronary
plaque volume reduces to a change in thickness. Therefore, sample
sizes and duration of therapy required to show effects of treatment
with intravascular ultrasound are substantially larger: in the
REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid-
Lowering) (7) study, 654 patients were followed 18 months to show
a difference between high-dose atorvastatin and pravastatin.
Finally, investigators wishing to measure effects of antiathero-
sclerotic therapy would be well served by measuring carotid plaque
volume using three-dimensional ultrasound.
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REPLY
As a follow-up to our study on the effects of aggressive versus
conventional lipid-lowering therapy by simvastatin in human
atherosclerotic lesions (1), Dr. Spence stated that “Corti et al.
found no difference in vessel wall area measured by magnetic
resonance imaging (MRI)” and that “investigators wishing to
measure effects of antiatherosclerotic therapy would be well served
by measuring carotid plaque volume using three-dimensional
ultrasound” on the importance of the methodology and location of
atherosclerotic lesions when measuring the effect of antiarterio-
sclerotic therapies. Our study (1) was the second publication from
a randomized, double-blind trial involving 51 newly diagnosed,
clinically asymptomatic hyperlipidemic patients. Changes in ath-
erosclerotic lesions were assessed by using high-resolution nonin-
vasive MRI. The major conclusion of our study is the importance
of lowering plasma low-density lipoprotein (LDL) cholesterol
levels rather that the statin dose. As such, we reported that the
observed changes in aortic plaque parameters were related to the
reduction in LDL-cholesterol levels rather than to the doses of
statin. The study design and early observations were published in
2001 (2).
Dr. Spence is partially correct in his statement that we found no
differences in plaque volume in the study. We did observe a
correlation with LDL-lowering and aortic lesion changes. Dr.
Spence is correct in that we did not achieve statistically significant
changes in the carotid lesions, although the percentages of volume
change were identical in both the aorta and carotids. These
observations strongly support the role of the severity/thickness of
the lesions at baseline as a major determinant for detecting the
effectiveness of the therapeutic interventions. In this regard, using
an MRI-based imaging modality and the same treatments but in a
population with more advanced disease (clinically documented
coronary artery disease), Lima et al. (3) reached a conclusion similar
to ours. In their study, the changes were significant after only six
months of treatment (3). The importance of lesion severity for
detecting treatment-induced changes in plaque volume is clearly
emphasized by these two studies. Furthermore, these findings have
been corroborated by studies performed more recently.
The major advantages of using MRI for plaque assessment are
the noninvasive approach and the high sensitivity and specificity of
this modality that permits a small sample size of subjects. This
observation has been confirmed by a recent study with five sites
that has reported sample size calculation for clinical trials using
MRI for quantitative assessment of carotid atherosclerosis (4).
We do agree with Dr. Spence that MRI is not the only imaging
modality capable of detecting changes in plaque lesions. The
objective of our study was not to conclude that MRI is the only
imaging modality to be used for such purpose. We want to
emphasize that the important fact in inducing lesion regression is
an effective and maintained lipid-lowering intervention. If the
intervention is effective, MRI and any of the other imaging
modalities should clearly validate the beneficial effects.
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Aspirin Resistance and
Atherothrombotic Disease
We read with interest the comprehensive review of “aspirin resistance”
by Mason et al. (1). We suggest, based on our recent experience, that
two less well-explored mechanisms may contribute to what is clearly
a composite of several processes.
Interindividual pharmocodynamic variability occurs with most
drugs. Aspirin is no different; thus aspirin resistance assays may
reflect pharmacodynamic heterogeneity. Mason et al. (1) identify
genotypic variation in cyclooxygenase (COX)-1 as a potential but
unproven pharmacodynamic mechanism. We recently explored
this hypothesis in a population with stable coronary artery disease
(CAD) and determined that COX-1 haplotype modulates platelet
response to aspirin determined by two established laboratory assays
of COX inhibition: arachidonic acid-induced platelet aggregation
and thromboxane B2 generation in serum. Much of the effect,
however, was associated with a single COX-1 haplotype carried by
12% of the population, and thus, although contributing to the
problem, this does not explain the higher rates of aspirin resistance
reported in several studies (2).
Mason et al. (1) also discuss pharmacokinetic resistance to
aspirin and specifically the role of drug interaction and dose
response; however, variability in aspirin formulation is another
possible factor. It is worth recalling that initial dose-finding studies
were performed with plain aspirin, which is rapidly absorbed from
the stomach and inhibits platelet cyclooxygenase in the presystemic
circulation. As mentioned by Mason et al. (1) dosing with 100 mg
is sufficient to completely inhibit platelet cyclooxygenase. Accord-
ingly, current American College of Cardiology/American Heart
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